Study of Olverembatinib (HQP1351) in Patients With CP-CML

This study is testing a drug called olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia (CML), a blood cancer, who have not responded to or cannot tolerate other targeted treatments. It includes two groups: patients who failed two or more prior treatments, and those with a specific resistant mutation called T315I. **You may be eligible if...** - You are 18 or older - You have been diagnosed with chronic myeloid leukemia in the chronic phase - Part A: You have tried and failed at least two approved targeted treatments (TKIs) - Part B: You have a T315I mutation in your cancer (a specific genetic change that makes many drugs less effective) - Your overall health and organ function are adequate **You may NOT be eligible if...** - Part A only: You have ever had a T315I mutation - You have an active serious infection - You are pregnant or breastfeeding - You have a gut condition that would affect how you absorb the drug - You are allergic to olverembatinib or a related drug (bosutinib) Talk to your doctor to see if this trial is right for you.